

**MERCK & CO., INC.**  
**OTHER FINANCIAL DISCLOSURES**  
**THIRD QUARTER**  
**2004**

**NET PRODUCT SALES DETAIL (millions of dollars)**

PRODUCT	3Q '04 vs. 3Q '03					
	TOTAL % CHG	TOTAL \$	U.S. % CHG	U.S. \$	Foreign % CHG	Foreign \$
AGGRASTAT	-25%	19	N/A	-	4%	19
ARCOXIA	*	61	N/A	-	*	61
CANCIDAS	40%	109	35%	65	49%	43
COZAAR / HYZAAR	14%	706	13%	260	14%	446
CRIXIVAN / STOCRIN	1%	65	-43%	9	14%	56
EMEND	*	14	*	13	*	1
FOSAMAX	13%	778	7%	443	22%	335
INVANZ	43%	16	27%	11	94%	5
MAXALT	-17%	84	-24%	57	2%	27
PRIMAXIN	-5%	162	-27%	42	6%	119
PROPECIA	14%	67	22%	33	8%	34
PROSCAR	42%	180	94%	91	12%	89
SINGULAIR	2%	626	-6%	447	26%	179
TIMOPTIC / TIMOPTIC XE	-1%	38	-53%	2	6%	36
TRUSOPT / COSOPT	15%	138	19%	60	12%	78
VASOTEC / VASERETIC	-8%	170	N/A	-	-10%	170
VIOXX <sup>(1)</sup>	-66%	175	-43%	148	-89%	27
ZOCOR	-13%	1,221	-14%	854	-10%	366
HEPATITIS VACCINES	-32%	48	-35%	40	-14%	8
VIRAL VACCINES	5%	167	3%	154	28%	13
OTHER VACCINES	2%	82	-1%	65	17%	17

\* 100% or over

N/A - Not Applicable

<sup>(1)</sup> Includes adjustments of \$-492 related to the withdrawal of Vioxx for customer returns of product previously sold.

**TOTAL SALES: VOLUME, PRICE, EXCHANGE**

	3Q '04	% CHG.	VOL	PX	FX
<b>TOTAL PHARMACEUTICAL SALES</b>	<b>\$ 5,538</b>	<b>-4%</b>	<b>-7</b>	<b>1</b>	<b>2</b>
U.S. (\$ MM)	3,390	-4%	-8	4	N/A
Foreign (\$ MM)	2,148	-4%	-7	-3	6

**MERCK & CO., INC.**  
**OTHER FINANCIAL DISCLOSURES**  
**YEAR-TO-DATE**  
**2004**

**NET PRODUCT SALES DETAIL (millions of dollars)**

PRODUCT	SEPTEMBER YTD `04 vs. SEPTEMBER YTD `03					
	TOTAL % CHG	TOTAL \$	U.S. % CHG	U.S. \$	Foreign % CHG	Foreign \$
AGGRASTAT	-15%	63	N/A	-	9%	63
ARCOXIA	*	153	N/A	-	*	153
CANCIDAS	61%	298	56%	172	67%	125
COZAAR / HYZAAR	15%	2,060	10%	735	18%	1,325
CRIXIVAN / STOCRIN	-15%	193	-73%	21	14%	173
EMEND	55%	29	46%	27	*	2
FOSAMAX	15%	2,329	5%	1,323	31%	1,006
INVANZ	71%	44	53%	31	*	13
MAXALT	-5%	218	-14%	137	16%	82
PRIMAXIN	-3%	465	-29%	108	9%	357
PROPECIA	11%	195	12%	94	11%	101
PROSCAR	23%	539	35%	269	13%	270
SINGULAIR	26%	1,891	23%	1,327	33%	564
TIMOPTIC / TIMOPTIC XE	-2%	114	-41%	7	2%	107
TRUSOPT / COSOPT	16%	402	16%	169	16%	233
VASOTEC / VASERETIC	-3%	537	N/A	-	-5%	537
VIOXX <sup>(1)</sup>	-18%	1,489	-20%	891	-15%	599
ZOCOR	2%	3,886	13%	2,713	-17%	1,173
HEPATITIS VACCINES	-20%	151	-22%	124	-6%	27
VIRAL VACCINES	2%	419	-	383	28%	36
OTHER VACCINES	-5%	180	-8%	139	8%	41

\* 100% or over

N/A - Not Applicable

<sup>(1)</sup> Includes adjustments of \$-492 related to the withdrawal of Vioxx for customer returns of product previously sold.

**TOTAL SALES: VOLUME, PRICE, EXCHANGE**

	YTD `04	% CHG.	VOL	PX	FX
<b>TOTAL PHARMACEUTICAL SALES</b>	<b>\$ 17,191</b>	<b>2%</b>	<b>-2</b>	<b>1</b>	<b>3</b>
U.S. (\$ MM)	10,099	-1%	-4	3	N/A
Foreign (\$ MM)	7,091	6%	0	-3	8

**MERCK & CO., INC.**  
**OTHER FINANCIAL DISCLOSURES**  
**THIRD QUARTER**  
**2004**

**OTHER (INCOME)/EXPENSE, NET FROM CONTINUING OPERATIONS (millions of dollars)**

	3Q `04	3Q `03	YTD 2004	YTD 2003
INTEREST INCOME	\$ (75.7)	\$ (66.9)	\$ (209.8)	\$ (236.5)
INTEREST EXPENSE	72.4	81.1	216.8	270.9
EXCHANGE (GAINS)/LOSSES	2.8	(1.7)	9.9	(25.1)
MINORITY INTERESTS	37.6	39.1	114.0	131.5
AMORTIZATION OF INTANGIBLES	4.6	4.4	14.3	14.9
Other, net	(45.9)	(38.9)	(385.2)	(270.2)
<b>TOTAL</b>	<b>\$ (4.2)</b>	<b>\$ 17.1</b>	<b>\$ (240.0)</b>	<b>\$ (114.5)</b>

**JOINT VENTURE SALES DETAIL (millions of dollars)**

All sales reported here are end-market JV sales, presented on a "NET" basis.

<b>Merial</b>	3Q `04	3Q `03	YTD 2004	YTD 2003
IVOMEK, HEARTGARD, other avermectins	\$ 139	\$ 141	\$ 335	\$ 352
FRONTLINE	224	183	569	485
Biologicals	120	106	343	306
Other Animal Health	55	55	165	152
Poultry Breeding	36	38	107	113
<b>TOTAL MERIAL SALES</b>	<b>\$ 574</b>	<b>\$ 523</b>	<b>\$ 1,519</b>	<b>\$ 1,408</b>

<b>Aventis Pasteur-MSD</b>	3Q `04	3Q `03	YTD 2004	YTD 2003
HEPATITIS VACCINES	\$ 20	\$ 18	\$ 61	\$ 55
VIRAL VACCINES	15	16	42	40
Other Vaccines	239	200	483	404
<b>TOTAL AP-MSD SALES</b>	<b>\$ 274</b>	<b>\$ 234</b>	<b>\$ 586</b>	<b>\$ 499</b>

<b>Merck / Schering-Plough Collaboration</b>	3Q `04	3Q `03	YTD 2004	YTD 2003
VYTORIN (Worldwide)	\$ 52	\$ -	\$ 56	\$ -
ZETIA (Worldwide)	293	136	725	305
<b>TOTAL</b>	<b>\$ 345</b>	<b>\$ 136</b>	<b>\$ 781</b>	<b>\$ 305</b>